JP7641967B2 - ヒト化ｃｌｄｎ１８．２抗体 - Google Patents

ヒト化ｃｌｄｎ１８．２抗体 Download PDF

Info

Publication number
JP7641967B2
JP7641967B2 JP2022534370A JP2022534370A JP7641967B2 JP 7641967 B2 JP7641967 B2 JP 7641967B2 JP 2022534370 A JP2022534370 A JP 2022534370A JP 2022534370 A JP2022534370 A JP 2022534370A JP 7641967 B2 JP7641967 B2 JP 7641967B2
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
amino acid
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505318A (ja
JP2023505318A5 (https=
JPWO2021111003A5 (https=
Inventor
バンメルト，ルーカス
サディルコワ，レンカ キリヒ
ヴァルトマイアー，ローレンツ
ベーリ，ロジェール
メービウス，ウルリヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sotio Biotech AS
Original Assignee
Sotio Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio Biotech AS filed Critical Sotio Biotech AS
Publication of JP2023505318A publication Critical patent/JP2023505318A/ja
Publication of JP2023505318A5 publication Critical patent/JP2023505318A5/ja
Publication of JPWO2021111003A5 publication Critical patent/JPWO2021111003A5/ja
Application granted granted Critical
Publication of JP7641967B2 publication Critical patent/JP7641967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022534370A 2019-12-06 2020-12-07 ヒト化ｃｌｄｎ１８．２抗体 Active JP7641967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214104.2 2019-12-06
EP19214104 2019-12-06
PCT/EP2020/084831 WO2021111003A1 (en) 2019-12-06 2020-12-07 Humanized cldn18.2 antibodies

Publications (4)

Publication Number Publication Date
JP2023505318A JP2023505318A (ja) 2023-02-08
JP2023505318A5 JP2023505318A5 (https=) 2023-10-24
JPWO2021111003A5 JPWO2021111003A5 (https=) 2023-10-24
JP7641967B2 true JP7641967B2 (ja) 2025-03-07

Family

ID=68808161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534370A Active JP7641967B2 (ja) 2019-12-06 2020-12-07 ヒト化ｃｌｄｎ１８．２抗体

Country Status (8)

Country Link
US (1) US20230030674A1 (https=)
EP (1) EP4069738A1 (https=)
JP (1) JP7641967B2 (https=)
KR (1) KR20220111308A (https=)
CN (1) CN114901696B (https=)
AU (1) AU2020398045A1 (https=)
CA (1) CA3159465A1 (https=)
WO (1) WO2021111003A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199830A1 (en) * 2020-12-23 2022-06-30 Lukas BAMMERT Tumor-specific claudin 18.2 antibody-drug conjugates
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
EP4349371A4 (en) 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
JP2024523166A (ja) * 2021-06-15 2024-06-28 ゼンコア インコーポレイテッド クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025078686A1 (en) 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
WO2025077829A1 (zh) * 2023-10-13 2025-04-17 信达细胞制药(苏州)有限公司 Cldn18.2抗体及car-t细胞在治疗cldn18.2阳性实体瘤中的应用
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528075A (ja) 2007-05-29 2010-08-19 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
WO2019173420A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015659A2 (en) 1998-09-16 2000-03-23 Zymogenetics, Inc. Stomach polypeptide zsig28
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9953140B2 (en) * 2013-03-15 2018-04-24 Intent Solutions, Inc. Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
AU2017294276B2 (en) 2016-07-08 2024-08-01 Crage Medical Co., Limited Antibody for anti-claudin 18A2 and use thereof
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019175617A1 (en) 2018-03-10 2019-09-19 Pratik Sharma Data redundancy and elimination module
SG11202007074PA (en) 2018-05-18 2020-08-28 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN114901365B (zh) * 2019-12-23 2025-07-15 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体
CA3199830A1 (en) * 2020-12-23 2022-06-30 Lukas BAMMERT Tumor-specific claudin 18.2 antibody-drug conjugates
BR112023027312A2 (pt) * 2021-06-23 2024-03-12 Cytune Pharma Imunocitocina
US20240350589A1 (en) * 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528075A (ja) 2007-05-29 2010-08-19 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
WO2019173420A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2023505318A (ja) 2023-02-08
CA3159465A1 (en) 2021-06-10
EP4069738A1 (en) 2022-10-12
AU2020398045A1 (en) 2022-06-09
WO2021111003A1 (en) 2021-06-10
KR20220111308A (ko) 2022-08-09
US20230030674A1 (en) 2023-02-02
CN114901696B (zh) 2025-08-05
CN114901696A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
JP7641967B2 (ja) ヒト化ｃｌｄｎ１８．２抗体
US20240100180A1 (en) Tumor-specific claudin 18.2 antibody-drug conjugates
CN113480656B (zh) 抗ror1抗体
JP7817162B2 (ja) 腫瘍特異的クローディン１８．２抗体
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
US20250163157A1 (en) Bispecific antibodies against cd277 and a tumor-antigen
WO2023027164A1 (ja) Ｒｏｓ（活性酸素種）産生増強剤
WO2022122709A1 (en) Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN120035449A (zh) 一种结合baffr和cd3的双特异性抗体及其应用
EA046743B1 (ru) Опухолеспецифические антитела против клаудина 18.2
HK40119369A (zh) 抗SIRP α抗体及其用途
KR20260049221A (ko) 변형된 e형 다중특이성 항체
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
HK40076375B (zh) 抗SIRPα抗体及其用途
BR122025029428A2 (pt) Anticorpo isolado anti-cd19, sequências de polinucleotídeo isolado e de ácido nucleico, vetores, célula hospedeira, método de expressar o anticorpo, conjugado anticorpo-droga, composição farmacêutica, uso do anticorpo, receptor de antígeno quimérico (car), célula t isolada, método para estimular uma resposta imune, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241115

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250225

R150 Certificate of patent or registration of utility model

Ref document number: 7641967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150